Transitional B cell selection during peripheral B lymphopenia and reconstitution
外周 B 淋巴细胞减少和重建期间的过渡 B 细胞选择
基本信息
- 批准号:7587459
- 负责人:
- 金额:$ 49.42万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-04-01 至 2012-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAntibodiesAutoimmune ProcessAutoimmunityB-LymphocytesBLyS receptorBone MarrowBromodeoxyuridineCellsChimera organismCoupledDataDevelopmentEquilibriumFamilyFamily memberFlow CytometryFrequenciesHomeostasisLabelLightLinkLymphocyteLymphoidLymphopeniaMarrowMeasuresModelingMonitorOutputPeripheralPharmaceutical PreparationsPlayPopulationReagentRoleSpecificityStagingTNF geneTestingTransgenic MiceWithholding Treatmentautoreactivitybasein vivoirradiationreceptorreconstitutionresearch study
项目摘要
DESCRIPTION (provided by applicant): BLyS plays a critical role in integrating B cell homeostasis with specificity-based tolerance mechanisms. This is evidenced by the effects of manipulating BLyS or its receptors, as well as the links between the BLyS/BLyS receptor family and humoral autoimmunity. Recent data and our preliminary results show that the proportion of newly formed B cells surviving transitional selection can be varied based on homeostatic demands. Thus, the stringency of negative selection is relaxed when the demand for newly formed lymphocytes is high, allowing autoreactive clonotypes to mature and enter the follicular and marginal zone pools. These observations suggest that upon cessation of treatments that ablate peripheral pools, altered homeostatic demands will compromise the normal balance of selection and homeostasis. Accordingly, we hypothesize that during lymphoid reconstitution following curtailed marrow output or peripheral B lymphopenia, selective thresholds will be relaxed. We further hypothesize that this will be governed by available BLyS and BLyS receptor levels, and that the emergence of autoreactive specificities can thus be modulated by controlling available BLyS. The studies herein will address these ideas. In aim 1, we will determine how transitional B cell throughput is influenced by reduced marrow output and peripheral B lymphopenia. These experiments will employ BrdU labeling coupled with lymphoid autoreconstitution, drug-induced peripheral B lymphopenia, and mixed marrow chimera studies to determine the throughput and fate of cells under these conditions. In aim 2 we will determine whether the stringency of transitional repertoire selection is relaxed during peripheral lymphopenia or reduced BM output. We will assess selection stringency by monitoring changes in repertoire composition, diversity and specificity across transitional and mature subsets. In addition, we will directly test whether autoreactive specificities normally eliminated at the transitional checkpoint are afforded entry to mature compartments. These experiments will use flow cytometry, limiting dilution and single cell specificity analyses in normal and transgenic mice. In aim 3, we will establish whether normal selection can be restored by adjusting BLyS levels or responsiveness during replenishment of peripheral pools. We will assess whether reduced available BLyS levels will restore normal selective stringency by in vivo treatment with soluble TACI Ig or neutralizing anti-BLyS antibody in normal and autoimmune models.
描述(由申请人提供):BLyS在整合B细胞稳态与基于特异性的耐受机制方面发挥着关键作用。这通过操纵BLyS或其受体的作用以及BLyS/BLyS受体家族与体液自身免疫之间的联系来证明。最近的数据和我们的初步研究结果表明,过渡性选择中存活的新形成的B细胞的比例可以根据稳态需求而变化。因此,当对新形成的淋巴细胞的需求很高时,阴性选择的严格性被放松,允许自身反应性克隆型成熟并进入滤泡和边缘区池。这些观察结果表明,一旦停止消融外周血池的治疗,改变的稳态需求将损害选择和稳态的正常平衡。因此,我们假设在骨髓输出减少或外周B淋巴细胞减少后的淋巴重建过程中,选择性阈值将放松。我们进一步假设,这将是由可用的BLyS和BLyS受体水平,并出现自身反应特异性,因此可以通过控制可用的BLyS调制。本文的研究将探讨这些想法。在目标1中,我们将确定骨髓输出减少和外周B淋巴细胞减少如何影响过渡性B细胞通量。这些实验将采用BrdU标记结合淋巴自动重建、药物诱导的外周B淋巴细胞减少症和混合骨髓嵌合体研究,以确定这些条件下细胞的通量和命运。在目标2中,我们将确定在外周淋巴细胞减少症或BM输出减少期间,过渡库选择的严格性是否放松。我们将通过监测过渡和成熟亚群的库组成、多样性和特异性的变化来评估选择严格性。此外,我们将直接测试是否自身反应性特异性通常消除在过渡检查点提供进入成熟区室。这些实验将在正常和转基因小鼠中使用流式细胞术、有限稀释和单细胞特异性分析。在目标3中,我们将确定是否可以通过调节BLyS水平或外周池补充期间的反应性来恢复正常选择。我们将评估在正常和自身免疫模型中,通过使用可溶性泰爱IG或中和抗BLyS抗体进行体内治疗,降低的BLyS水平是否会恢复正常的选择性严格性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michael Paul Cancro其他文献
Michael Paul Cancro的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michael Paul Cancro', 18)}}的其他基金
Mechanistic studies of BLyS-mediated modulation in HIV-1 Env-specific antibody responses
BLyS 介导的 HIV-1 Env 特异性抗体反应调节机制研究
- 批准号:
8933717 - 财政年份:2015
- 资助金额:
$ 49.42万 - 项目类别:
Mechanistic studies of BLyS-mediated modulation in HIV-1 Env-specific antibody responses
BLyS 介导的 HIV-1 Env 特异性抗体反应调节机制研究
- 批准号:
9212095 - 财政年份:2015
- 资助金额:
$ 49.42万 - 项目类别:
Mechanistic studies of BLyS-mediated modulation in HIV-1 Env-specific antibody responses
BLyS 介导的 HIV-1 Env 特异性抗体反应调节机制研究
- 批准号:
9010936 - 财政年份:2015
- 资助金额:
$ 49.42万 - 项目类别:
Transitional B cell selection during peripheral B lymphopenia and reconstitution
外周 B 淋巴细胞减少和重建期间的过渡 B 细胞选择
- 批准号:
8072945 - 财政年份:2010
- 资助金额:
$ 49.42万 - 项目类别:
Transitional B cell selection during peripheral B lymphopenia and reconstitution
外周 B 淋巴细胞减少和重建期间的过渡 B 细胞选择
- 批准号:
7878468 - 财政年份:2009
- 资助金额:
$ 49.42万 - 项目类别:
Transitional B cell selection during peripheral B lymphopenia and reconstitution
外周 B 淋巴细胞减少和重建期间的过渡 B 细胞选择
- 批准号:
7390741 - 财政年份:2007
- 资助金额:
$ 49.42万 - 项目类别:
Transitional B cell selection during peripheral B lymphopenia and reconstitution
外周 B 淋巴细胞减少和重建期间的过渡 B 细胞选择
- 批准号:
7791400 - 财政年份:2007
- 资助金额:
$ 49.42万 - 项目类别:
Transitional B cell selection during peripheral B lymphopenia and reconstitution
外周 B 淋巴细胞减少和重建期间的过渡 B 细胞选择
- 批准号:
8046330 - 财政年份:2007
- 资助金额:
$ 49.42万 - 项目类别:
Transitional B cell selection during peripheral B lymphopenia and reconstitution
外周 B 淋巴细胞减少和重建期间的过渡 B 细胞选择
- 批准号:
7250657 - 财政年份:2007
- 资助金额:
$ 49.42万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 49.42万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 49.42万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 49.42万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 49.42万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 49.42万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 49.42万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 49.42万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 49.42万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 49.42万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 49.42万 - 项目类别: